Mfg Part Number
Ab02226-5.3

Vector Labs Ab02226-5.3 Anti-ganglioside GD3 [KM8871], Mouse IgG3, Fc Silent™, kappa (200 μg)

Quick Overview
This antibody was originally raised as a mouse IgG3 (clone KM641) which was turned into a mouse/human chimeric antibody KM871 and, finally, humanized by complementarity-determining region grafting and designated as KM8871 (Shitara et al., 1993; pmid: 8500110; Nakamura et al., 2001; pmid: 11499811).
$517.40
Order will ship within 1-3 business days
Add to Wish List
Product Class:Purified
Clone ID:KM8871
Heavy Chain Modification:Fc Silent™
Synonyms:ganglioside; C68H121N3O29; (2S,4S,5R)-5-acetamido-6-[(1S,2R)-2-[(2S,4S,5R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,6R)-6-[(E,2S,3R)-2-(hexadecanoylamino)-3-hydroxyoctadec-4-enoxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxyoxane-2-carboxylic acid; CHEBI:89636; d18:1/20:0
Amount:200 μg
Application Codes Clone:Therapeutics development; neutralizing; ELISA
Shipping Temperature:Wet Ice
Buffer Composition:PBS with 0.02% Proclin 300.
Original Format:IgG3
Storage Temperature:Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Specificity Statement:KM8871 recognizes ganglioside GD3, a prominent ganglioside of human melanoma, melanocytes and other cells of neuroectodermal origin. It cross-reacted weakly with GQ1b.
Application Notes:Ganglioside G3 is one of the major gangliosides expressed on most human cancers of neuroectodermal and epithelial origin and is a potential target for passive immunotherapy with monoclonal antibodies. This clone (KM8871) is recommended for the research and development of potential therapeuic agents for immunotherapy and target validation of ganglioside-based vaccine therapy (Nakamura et al., 2001; pmid: 11499811). The potent binding of the humanized antibody KM8871 to the ganglioside GD3 was confirmed by ELISA testing (Nakamura et al., 2001; pmid: 11499811). It was also demonstrated that KM8871 was able to induce CDC (complement-dependent cytotoxicity) and strong ADCC (antibody-dependent cellular cytotoxicity) against ganglioside GD3-expressing cancer cells (Nakamura et al., 2001; pmid: 11499811). Consequently, this humanized antibody can be further investigated as a potential therapetic candidate against various neuroectodermal and epithelial cancers, either alone or with active molecules conjugated to it.
More Information
Brand Vector Labs
UNSPSC 12161500